Literature DB >> 24453066

Identification of men with the highest risk of early disease recurrence after radical prostatectomy.

Debasish Sundi1, Vinson Wang, Phillip M Pierorazio, Misop Han, Alan W Partin, Phuoc T Tran, Ashley E Ross, Trinity J Bivalacqua.   

Abstract

BACKGROUND: Men destined to have early biochemical recurrence (BCR) following radical prostatectomy (RP) may be optimal candidates for multimodal treatment. Here we identified pre-operative predictors of early BCR within a surgical cohort who recurred.
METHODS: An institutional prostate cancer (PCa) database containing over 20,000 patients was queried to identify 1,471 men who had BCR after RP, and pre-operative predictors of early versus late BCR were assessed. Early BCR was defined as recurrence within 1 year after RP. Within the recurrence cohort, those with National Comprehensive Cancer Network (NCCN) high-risk features were more likely to experience early BCR. Therefore, in all NCCN high-risk men in the database, we abstracted detailed pathologic biopsy data. Among 753 high-risk men, 41 alternate multivariable criteria were assessed for their ability to predict early BCR in crude and adjusted logistic regression models.
RESULTS: The criteria that best identified those likely to experience early BCR are primary Gleason pattern 5 on biopsy or ≥4 cores containing pattern 4 (odds ratio 3.17, P < 0.001). These criteria included 26.7% of NCCN high-risk men. Additionally, these criteria selected for men within the high-risk classification who were at significantly higher risk of subsequent metastasis (adjusted hazard ratio 3.04, P < 0.001) and cancer-specific death (adjusted hazard ratio 3.27, P < 0.001).
CONCLUSIONS: In men with PCa who present with high-risk features, pre-operative criteria have the ability to discriminate the subgroup most likely to experience early BCR after RP. Men at risk for early disease recurrence may be the most suitable candidates for multimodal therapy.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  early biochemical recurrence; intraoperative therapy; multimodal therapy; prostate cancer

Mesh:

Year:  2014        PMID: 24453066      PMCID: PMC4076164          DOI: 10.1002/pros.22780

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

Review 2.  May intra-operative radiotherapy have a role in the treatment of prostate cancer?

Authors:  Marco Krengli; Carlo Terrone; Barbara Alicja Jereczek-Fossa; Debora Beldì; Roberto Orecchia
Journal:  Crit Rev Oncol Hematol       Date:  2011-09-16       Impact factor: 6.312

3.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

4.  Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

Authors:  Theodorus H Van der Kwast; Michel Bolla; Hein Van Poppel; Paul Van Cangh; Kris Vekemans; Luigi Da Pozzo; Jean-Francois Bosset; Karl H Kurth; Fritz H Schröder; Laurence Collette
Journal:  J Clin Oncol       Date:  2007-09-20       Impact factor: 44.544

5.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

6.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Authors:  John J Coen; Anthony L Zietman; Harjot Thakral; William U Shipley
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

8.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Authors:  Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

10.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450

View more
  10 in total

1.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

2.  Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.

Authors:  Sean P Stroup; Daniel M Moreira; Zinan Chen; Lauren Howard; Jonathan H Berger; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  J Urol       Date:  2017-07-11       Impact factor: 7.450

Review 3.  Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

Authors:  Min Yuen Teo; Matthew J O'Shaughnessy; Sean M McBride; Herbert A Vargas; Howard I Scher
Journal:  Nat Rev Clin Oncol       Date:  2017-10-17       Impact factor: 66.675

4.  Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.

Authors:  Takuya Koie; Koji Mitsuzuka; Takahiro Yoneyama; Shintaro Narita; Sadafumi Kawamura; Yasuhiro Kaiho; Norihiko Tsuchiya; Tatsuo Tochigi; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama; Tohru Yoneyama; Yuki Tobisawa
Journal:  Int J Clin Oncol       Date:  2014-04-29       Impact factor: 3.402

Review 5.  The very-high-risk prostate cancer: a contemporary update.

Authors:  R Mano; J Eastham; O Yossepowitch
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-09-13       Impact factor: 5.554

6.  Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?

Authors:  Akram Saad; Jeffrey Goldstein; Yaacov R Lawrence; Benjamin Spieler; Raya Leibowitz-Amit; Raanan Berger; Tima Davidson; Damien Urban; Lev Tsang; Dror Alezra; Ilana Weiss; Zvi Symon
Journal:  Radiat Oncol       Date:  2017-01-06       Impact factor: 3.481

7.  Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.

Authors:  Xianghong Zhou; Qingyang Ning; Kun Jin; Tao Zhang; Xuelei Ma
Journal:  BMC Cancer       Date:  2020-02-04       Impact factor: 4.430

8.  Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study.

Authors:  Xianghong Zhou; Shi Qiu; Kun Jin; Qiming Yuan; Di Jin; Zilong Zhang; Xiaonan Zheng; Jiakun Li; Qiang Wei; Lu Yang
Journal:  Front Surg       Date:  2021-11-26

9.  A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.

Authors:  Darren M C Poon; Jing Yuan; Bin Yang; Oi-Lei Wong; Sin-Ting Chiu; George Chiu; Kin-Yin Cheung; Siu-Ki Yu; Raymond W H Yung
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

10.  Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Authors:  Kazuhiro Nagao; Hideyasu Matsuyama; Hiroaki Matsumoto; Takahito Nasu; Mitsutaka Yamamoto; Yoriaki Kamiryo; Yoshikazu Baba; Akinobu Suga; Yasuhide Tei; Satoru Yoshihiro; Akihiko Aoki; Tomoyuki Shimabukuro; Keiji Joko; Shigeru Sakano; Kimio Takai; Shiro Yamaguchi; Jumpei Akao; Seiji Kitahara
Journal:  Int J Clin Oncol       Date:  2018-03-27       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.